Company news
Prescient Therapeutics Limited (ASX:PTX) news
Prescient Therapeutics Limited news releases on 6ix. Latest, Aug 24, 2022: Prescient Therapeutics Launches Share Purchase Plan
Press releases — page 2
Prescient Therapeutics Launches Share Purchase Plan
August 24, 2022
Appendix 4E and 2022 Annual Report
August 23, 2022
PTX agreement with Thermo Fisher for scalable OmniCAR
August 17, 2022
PTX OmniCAR cell manufacturing contract for clinical trials
August 15, 2022
June 2022 Quarterly Update and Appendix 4C
July 24, 2022
US FDA Grants Orphan Drug Designation to PTX-100 for PTCL
July 14, 2022
Key OmniCAR Patent Granted in US
July 4, 2022
PTX CellPryme-M presentation
June 7, 2022
PTX unveils new clinic-ready CAR-T enhancement platform
June 7, 2022
PTX-200 AML expansion after another complete response
May 9, 2022
March 2022 Quarterly Update and Appendix 4C
April 28, 2022
Recruitment Open for Expansion Cohort of Phase 1B Study
April 5, 2022
December 2021 Quarterly Update and Appendix 4C
January 30, 2022
September 2021 Quarterly Activities and Appendix 4C
October 27, 2021
Investor Presentation - October 2021
October 12, 2021
PTX data demonstrates key OmniCAR features in next gen CAR-T
October 12, 2021
Appendix 4E and 2021 Annual Report
August 30, 2021
June 2021 Quarterly Activities and Appendix 4C
July 29, 2021
PTX-100 trial advances following successful Phase 1b
July 26, 2021
PTX successful immunogenicity testing of OmniCAR
July 4, 2021
PTX Completes CAR-T Manufacturing Milestone for OmniCAR
June 23, 2021
Response to ASX Price Query
June 3, 2021
PTX signs CAR-T agreement with Peter MacCallum
May 10, 2021
March 2021 Quarterly Update and Appendix 4C
April 29, 2021
PTX-200 AML Trial Progresses to Higher Dose
April 22, 2021
December 2020 Quarterly Update and Appendix 4C
January 27, 2021
PTX announces 3 next-gen CAR-T programs with OmniCAR
January 17, 2021
Prescient Receives $1.03m R&D Tax Rebate
November 10, 2020
September 2020 Quarterly Update and Appendix 4C
October 19, 2020
Response to ASX Query
September 16, 2020
PTX Raises $7 million via Strongly Supported Placement
August 25, 2020
Appendix 4E and 2020 Annual Report
August 25, 2020
Successful SPP Closed Early
August 18, 2020
Extension of Share Purchase Plan
August 14, 2020
PTX Announces Cell Therapy Collaboration with Peter Mac
August 13, 2020
PTX-100 progresses to next cohort in basket clinical study
August 11, 2020
PTX-200 AML Trial Progresses to Next Dose Level
August 3, 2020
June 2020 Quarterly Update and Appendix 4C
July 21, 2020
2 PTX Assets Chosen in Doherty Institute COVID-19 Program
July 21, 2020
Trading Pause
July 20, 2020
Reinstatement to Official Quotation
May 25, 2020
PTX signs next-gen anti-cancer platform from Penn & Oxford
May 25, 2020
Voluntary Suspension
May 25, 2020
Pause in Trading
May 21, 2020
PTX-100 progresses to new dose, adds new site
April 21, 2020
March 2020 Quarterly Update and Appendix 4C
April 15, 2020
December 2019 Appendix 4C - Quarterly
January 31, 2020
PTX-200 High Overall Response in Ph2a Breast Cancer trial
December 22, 2019
Encouraging data from PTX-200 ovarian cancer trial
December 11, 2019
Third complete response in PTX-200 AML Trial
November 26, 2019